Navigation Links
Cytos Biotechnology Reports Results from Phase IIa Study with,CYT003-QbG10 in Patients Suffering from Atopic Dermatitis

SCHLIEREN (Zurich), Switzerland, July 3, 2007 - Cytos Biotechnology AG (SWX:CYTN) announced today results from a phase IIa study with CYT003-QbG10 in atopic dermatitis. CYT003-QbG10 is an immunotherapeutic product candidate currently in development for the treatment of allergic diseases. The present study aimed to assess safety, tolerability and exploratory efficacy of the product candidate in a new indication, namely atopic dermatitis. The study was designed as a placebo-controlled, randomized and double-blind trial in 36 patients suffering from mild to moderate atopic dermatitis (AD). Exploratory efficacy was determined according to the Eczema Area and Severity Index (EASI), a commonly applied test to assess the extent and severity of AD.

Treatment with CYT003-QbG10 was safe and generally well tolerated. In both the placebo-treated and CYT003-QbG10-treated groups a similar reduction of the EASI scores was measured over the study period indicating no treatment effect for CYT003-QbG10 in atopic dermatitis at the dose level tested in this trial.

Dr. Wolfgang Renner, CEO of Cytos Biotechnology, commented: “While CYT003-QbG10 has shown strong efficacy in conjunction with a specific allergen in patients with house dust mite allergy, we are still in the process of identifying the best treatment parameters for its application as a monotherapy. This monotherapy has achieved first promising results in grass pollen and also house dust mite allergy. For the latter indication we are now testing higher doses of the product candidate. Based on the outcome of these studies we will then also consider the path forward in atopic dermatitis.”

About the phase IIa study
The randomized, double-blind and placebo-controlled phase IIa study included 36 male and female patients aged 18 to 65 and suffering from mild to moderate AD. Upon entry into the study, the extent and severity of the disease was assessed by the Eczema Area Severit y Index (EASI), a commonly applied test for AD. The study participants were randomized into two treatment groups with 18 patients each and received 6 weekly subcutaneous injections of either 300 ?g CYT003-QbG10 or placebo. Two weeks after the last dose, the disease status of the patients was again assessed by the EASI.

About allergic diseases and atopic dermatitis
Allergy as a whole is a multi-faceted disease and clinically manifests in various allergic disorders including allergic rhinitis, asthma, atopic dermatitis and food hypersensitivity. On the immunological level, so called T helper 2-type (Th2) immune responses are considered crucial for the initiation and maintenance of allergy. The prevalence of allergic diseases has dramatically increased over the last decades, especially in industrialized countries. It is estimated that today more than 20% of the world population suffers from allergic diseases1.

AD is a certain type of eczema. It is a common chronic skin disease considered to be linked to an “allergic” Th2 type immune status of the patients. It most often begins in infancy and an estimated 20% of infants and young children experience disease symptoms. Roughly 60% of those continue to have AD also in adulthood2. Children with AD are at greater risk for developing other allergic diseases like rhinitis or asthma later in life. AD is characterized by a hypersensitivity reaction occurring in the skin that causes chronic inflammation and renders the skin dry, itchy and scaly. Irritants (e.g. wool, soap), allergens and emotional stress exacerbate disease symptoms and further trigger the overactive immune system. There is no cure available. Current medications such as immunomodulators, corticosteroids or antihistamines address disease symptoms only and may be associated with sideeffects, especially upon long-term use.

About CYT003-QbG10
CYT003-QbG10 is an immunotherapeutic product in development for the treatment of allergic diseases. It consists of the Immunodrug™ QbG10 which is comprised of the virus-like particle Qb filled with a synthetic immunostimulatory DNA sequence called G10. CYT003-QbG10 is designed as a disease-modifying treatment and aims to induce a potent Th1 type immune response in order to suppress an “allergic” Th2 type immune response. An open-label phase IIa study with CYT003-QbG10 combined with an allergen extract of house dust mites at a standard dose showed excellent longterm efficacy in patients allergic to dust mites. Furthermore, two placebo-controlled phase IIa
studies with CYT003-QbG10 monotherapy delivered positive results in patients suffering from grass pollen and house dust mite allergy.

For further information please contact: Cytos Biotechnology AG, Wagistrasse 25, CH-8952 Schlieren (Zurich)
Dr. Claudine Blaser
Director Corporate Communications
Phone: +41 44 733 47 20
Fax: +41 44 733 47 18

About Cytos Biotechnology
Cytos Biotechnology AG is a public Swiss biotechnology company that specializes in the discovery, development and commercialization of a new class of biopharmaceutical products – the Immunodrugs™. Immunodrugs™ are intended for use in the treatment and prevention of common chronic diseases, which afflict millions of people worldwide. Immunodrugs™ are designed to instruct the patient’s immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. Taking advantage of the high flexibility of its Immunodrug™ platform, Cytos Biotechnology has built a full pipeline of different Immunodrug™ candidates in various disease areas, of which 6 are currently in clinical developm ent. The Immunodrug™ candidates are developed both in-house and together with Novartis and Pfizer Animal Health. Founded in 1995 as a spin-off from the Swiss Federal Institute of Technology (ETH) in Zurich, the company is located in Schlieren (Zurich). Currently, the company has 129 employees. Cytos Biotechnology AG has been listed on the SWX Swiss Exchange (SWX:CYTN) since October 2002.

1 Prevention of Allergy and Allergic Asthma (2003), World Health Organization (WHO).
2 Atopic Dermatitis (2003), National Institutes of Health, Publication No. 03-4272.

Atopic dermatitis: a chronic skin disease; a certain type of eczema. Is accompanied by an inherited tendency to develop allergic diseases.
Disease-modifying: in contrast to symptomatic treatment, a disease-modifying treatment aims at addressing the cause of disease and to modify disease progression.
DNA: deoxyribonucleic acid; genetic information of an organism.
Double-blind: a set-up often applied in clinical trials where neither the doctor nor the patient knows if placebo or the active drug substance is applied.
EASI: Eczema Area and Severity Index (EASI), a commonly applied test to assess the extent and severity of AD.
Hypersensitivity: an excessive immune reaction. Immunotherapeutic: a product aimed at activation of the immune system to modify and interfere with a certain disease process.
Monotherapy: treatment with one drug as opposed to combination therapy. Here the term refers to treatment with CYT003-QbG10 alone in contrast to a regimen where CYT003-QbG10 is combined to an allergen extract (i.e. CYT005-AllQbG10).
Phase IIa: a clinical trial that examines a new drug candidate’s safety and exploratory efficacy and may include
between 10 and 100 patients.
Placebo: dummy medical treatment.
QbG10: Cytos Biotechnology’s Immunodrug™ Qb filled with the immunostimulatory D NA sequence G10.
Randomized: random assignation of clinical trial participants to different treatment groups.
Th1 and Th2 type immune responses: describe T helper cell responses. T helper cells are a subset of T cells that
secrete a variety of mediators (cytokines) playing a role for other immune cells. A Th1 type immune response is
usually induced by viral or bacterial infection, or also by potent vaccination / immunotherapy. A Th2 type
immune response usually manifests an allergic reaction.

This foregoing press release may contain forward-looking statements that include words or phrases such as “will”, “considered to”,
“designed at”, “aimed to”, “determined to”, “intend” or other similar expressions. These forward-looking statements are subject to a
variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ
significantly from those presented. There can be no assurance that any further therapeutic entities will enter clinical trials, that clinical
trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any
drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that
drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements.
The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This
document does not constitute an offer or invitation to subscribe or purchase any securities of Cytos Biotechnology AG.

Related medicine technology :

1. Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for the Treatment of Psoriasis
2. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
3. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
4. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
5. Prana Biotechnology Presents New Key Findings on PBT2
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
7. Generex Biotechnology Vaccine Strategy Presented at International Conference in London
8. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting
9. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
10. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
11. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
Post Your Comments:
(Date:10/2/2017)... -- The Rebound mobile app is poised to become a ... of prescription drug addiction. The app empowers users to develop ... down their dosage in a safe, controlled manner while maximizing ... first 100,000 people to sign up will enjoy 3 months ... ...
(Date:9/27/2017)... -- Commended for their devotion to personalized service, SMP Pharmacy Solutions ... in the South Florida Business Journal,s 50 Fastest-Growing Companies, and ... the national specialty pharmacy has found its niche.  To that ... be honored by SFBJ as the 2017 Power Leader in ... receive his award in October, Bardisa said of the three ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... a leader in post-acute health care, have expanded their existing home health joint ... Health. , AccentCare has been operating a joint venture home health company with ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
(Date:10/12/2017)... GRAND RAPIDS, Mich. (PRWEB) , ... October 12, ... ... OnSite Wellness, has been named one of Michigan’s 2017 Best and Brightest in ... Best and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 ...
Breaking Medicine News(10 mins):